Meta-Analysis of Prevalence and Risk Factors for Cognitive Decline and Improvement After Transcatheter Aortic Valve Implantation

Erica S. Ghezzi, BPsys(Hons)\textsuperscript{b,*}, Tyler J. Ross, BPsys(Hons)\textsuperscript{a}, Daniel Davis, PhD, MRCP\textsuperscript{b}, Peter J. Psaltis, MBBS (Hons), PhD, FRACP, FCSANZ\textsuperscript{c,d,e}, Tobias Loetscher, PhD\textsuperscript{a}, and Hannah A.D. Keage, PhD\textsuperscript{a}

Changes to cognition, both decline and improvement, are commonly reported after transcatheter aortic valve implantation (TAVI). However, previous systematic reviews and meta-analyses have missed these subgroups by assessing whole-group-averages for cognitive outcomes. We sought to pool estimates to identify the prevalence of cognitive decline and improvement after TAVI, as well as associated factors for these outcomes. A systematic review identified 15 articles appropriate for meta-analysis. When robust cognitive change definitions were employed, the pooled prevalence of incident cognitive impairment up to 1-, 1 to 6-, and ≥6-months post-TAVI was 7%, 14%, and 12%, respectively. For cognitive improvement, the prevalence from 1 to 6 months and ≥6 months after TAVI was estimated to be 19% and 11%, respectively. Two factors were associated with these cognitive outcomes: (1) using a cerebral embolic protection device was associated with decreased prevalence of cognitive decline up to 1-week post-TAVI; (2) baseline cognitive impairment had a large association with post-TAVI cognitive improvement. In conclusion, cognitive decline and cognitive improvement are experienced by approximately 7% to 19% of patients after TAVI, respectively. Those with the lowest cognitive performance pre-TAVI appear to have the most to gain in terms of cognitive improvement post-TAVI. Identifying further predictive factors for cognitive decline and improvement post-TAVI will facilitate a personalized-medicine approach for cognitive care and prognosis. © 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/) (Am J Cardiol 2020;127:105–112)

Since its introduction in 2002, transcatheter aortic valve implantation (TAVI) has become standard care for severe symptomatic aortic stenosis in patients not suitable for surgical aortic valve replacement.\textsuperscript{1} TAVI has shown increased survival and reduced all-cause mortality compared with the surgical alternative, as well as long-term improvements in quality of life and functional capabilities.\textsuperscript{1-3} Previous systematic review and meta-analyses of cognitive outcomes after TAVI have shown, at a group-level, preservation (i.e., no significant decline or improvement) of cognitive function after TAVI.\textsuperscript{4,5} However, not all patient experiences align with this conclusion. Individual studies report a variety of cognitive outcomes (decline, no change, and improvement) experienced after TAVI.\textsuperscript{6-10} Knowledge of which patients are expected to cognitively decline and improve after TAVI is clinically relevant and important. This systematic review and meta-analysis synthesized existing literature to provide estimates of the prevalence of cognitive decline and improvement after TAVI. Additionally, an analysis of reported risk factors for cognitive decline and protective factors for cognitive improvement was conducted.

Methods

This review was conducted in adherence with the Preferred Reporting Items for Systematic reviews and Meta-Analysis statement.\textsuperscript{11} Abstract, full-text screening and data extraction were conducted by 2 independent reviewers (E. S. Ghezzi and T.J. Ross). Conflicts were resolved through discussion. PsycINFO, Ovid Emcare, EMBASE, Pubmed, and Cochrane databases were searched using the search terms listed in the Supplement. Studies published from the time of the first TAVI procedure in 2002 until the search date (November 27, 2019) were included.

Inclusion criteria were peer-reviewed, full-text, English language studies investigating adult participants who
underwent a TAVI procedure. Studies had to include both a pre- and postprocedure cognitive measure and report the number of participants who declined and/or improved post-TAVI relative to preprocedure cognitive function. Studies were excluded if only group-level changes to cognition were reported (i.e., average cognitive score pre- and post-TAVI), and if only mixed-samples were reported (e.g., TAVI and surgical aortic valve replacement). Case studies (n = 1), dissertations, book chapters, protocol papers, reviews, news articles, conference abstracts, letters to the editor, editorials and commentary publications were also excluded.

The quality of evidence and risk of bias were assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence Data (Supplement Table 1).

Data extracted included country, sample size, age, gender, definition of cognitive decline/improvement, frequency of cognitive decline/improvement at reported time-points post-TAVI, and reported predictive factors (pre-, intra-, and postoperative variables) for cognitive decline and improvement. Cognitive decline or improvement based on all cognitive assessments were included, from global cognitive function assessments (e.g., Montreal Cognitive Assessment [MoCA], Mini Mental State Examination [MMSE]) to individual tests (e.g., Trail Making Test, Digit Substitution Test, etc.). When 1 study reported 2 methods of determining cognitive decline within the same participants (e.g., decline in MoCA or MMSE), data from both methods were averaged within analyses.

Meta-analyses were completed using the Comprehensive Meta-Analysis Software (Version 3). Random-effects modelling was used due to considerable heterogeneity in study sample and design of included studies. Heterogeneity was assessed using the I² statistic, with values of 25%, 50%, and 75% interpreted as small, moderate and large, respectively.

Cognitive decline and improvement data were separated into 3 time-points post-TAVI: <1 month; ≥1 month and <6 months; and ≥6 months. Meta-analyses were then conducted to estimate prevalence of cognitive decline and cognitive improvement at each time-point. When 1 study reported 2 data points within 1 time period analysis (e.g., 2 and 7 days are both <1 month), both time points (measuring the same sample of participants) were averaged within analyses.

We further split these prevalence estimates by categorizing each study-reported definition of cognitive change (e.g., cognitive decline defined as ≥20% decrease in MoCA score) as relaxed or robust. Cognitive change definitions were categorized as relaxed if they did not attempt to account for measurement error or bias; simply counting any difference between baseline to post-TAVI test scores (≥1 point) as a relevant change, indicative of cognitive decline or improvement. Conversely, we defined robust cognitive change definitions as those which attempted to account for normal score variation in some way, either through a standard deviation cutoff, a reliable change index or a score change (from baseline to post-TAVI) on a single cognitive test capturing general functioning (e.g., MoCA or MMSE) of ≥3 points. Analyses to estimate the prevalence of cognitive decline or improvement based on cognitive change definition (robust and relaxed) were conducted at each time-point for which 2 or more papers reported cognitive change.

Risk factors were synthesized in the meta-analysis if they had been reported in at least 2 of the included studies. Ten independent risk factors met this criterion. The calculated outcomes are odds ratios (OR) for dichotomous risk factors and mean difference (MD) for continuous risk factors. Precision of the OR or MD was quantified by a 95% confidence interval [CI] for each analysis.

Results

A total of 5,993 articles were identified, 4,632 after duplicates were removed. One thousand and sixty seven met criteria for full-text review and 15 of these were included for final review and meta-analyses (Supplement Figure 1). All 15 studies reported incidence of cognitive decline post-TAVI and 5 of these additionally reported the incidence of cognitive improvement post-TAVI (see Tables 1 and 2, respectively, for overview of these studies).

The pooled prevalence of cognitive decline (regardless of relaxed/robust definition) was 18% (95% CI 10% to 31%, \( I^2 = 88.77 \)) up to 1 month, 25% (95% CI 17% to 35%, \( I^2 = 65.11 \)) from 1 to 6 months, and 12% (95% CI 7% to 19%, \( I^2 = 48.09 \)) 6 months and beyond after TAVI (Figure 1).

The pooled prevalence of cognitive improvement was 31% (95% CI 16% to 52%, \( I^2 = 77.56 \)) from 1 to 6 months (regardless of relaxed/robust definition), and 11% (95% CI 8% to 16%, \( I^2 = 0 \)) 6 months and beyond (based on robust definition) after TAVI (Figure 1). The prevalence of cognitive improvement up to 1 month after TAVI was not analyzed as only 1 study reported relevant data (50% cognitive improvement at discharge).

The pooled prevalence of cognitive decline up to 1-month post-TAVI when using a relaxed cognitive change definition was 35% (95% CI 23% to 49%, \( I^2 = 79.66 \) versus 7% (95% CI 4% to 13%, \( I^2 = 43.28 \)) when a robust cognitive change definition was employed (Figure 1). The pooled prevalence of cognitive decline 1 to 6 months post-TAVI when using a relaxed cognitive change definition was 33% (95% CI 26% to 42%, \( I^2 = 37.42 \)) and 14% (95% CI 6% to 29%, \( I^2 = 63.54 \)) when a robust cognitive change definition was utilized (Figure 1). The pooled prevalence of cognitive improvement 1 to 6 months post-TAVI when using a relaxed cognitive change definition was 47% (95% CI 28% to 66%, \( I^2 = 55.76 \)) and 19% (95% CI 11% to 30%, \( I^2 = 0 \)) when a robust cognitive change definition was used (Figure 1).

Forest plots and heterogeneity statistics for prevalence analyses can be seen in Supplement Table 2 and Supplement Table 3.

Ten risk factors for the development of cognitive decline after TAVI were separately analyzed (see Table 3 and Supplement Table 4). These comprised 8 preprocedural factors (age, atrial fibrillation, body mass index, diabetes, gender, hypertension, baseline cognitive impairment, and stroke/TIA), 1 intraprocedural factor (cerebral protection device) and 1 postprocedural factor (stroke). Sufficient data were
Table 1
Summary of included studies which report cognitive decline following transcatheter aortic valve implantation

| Time-point       | Study*                  | Country                | Timing of assessment (post-TAVI) | N at time-point | Age at time-point (years)** | Cognitive decline | Cognitive assessment | Cognitive decline definition | Robust/relaxed definition |
|------------------|-------------------------|------------------------|----------------------------------|----------------|-----------------------------|-------------------|----------------------|--------------------------|--------------------------|
| <1 month         | Fanning (2017)          | Australia              | 3 days                           | 31             | 82.4 (7.7)                  | 9.7% MoCA         | Decrease ≥ 20%        | Robust                   |
|                  | Fanning (2016)          | Australia              | 3 days                           | 40             | 81.7 (6.9)                  | 5.0% MoCA         | Decrease ≥ 20%        | Robust                   |
|                  | Ghanem (2013)           | Germany                | 3 days                           | 111            | 80 (6)                      | 5.4% RBANS         | Decline > 1SD         | Robust                   |
|                  | Gleason (2016)          | USA                    | Discharge                        | 79             | -                           | 2.5% MMSE          | Decrease > 4 points   | Robust                   |
|                  | Haussig (2016)          | Germany                | 2 days                           | 72             | -                           | 61.1% MoCA         | Decrease ≥ 1 point    | Relaxed                  |
|                  |                         |                        | 7 days                           | 72             | -                           | 48.6% MoCA         | Decrease ≥ 1 point    | Relaxed                  |
|                  | Knipp (2013)            | Germany                | 10.7 ± 4.9 days                  | 22             | -                           | 18.2% Mixed test battery 1 | CCS ≤ −2             | Robust                   |
|                  | Lansky (2015)           | Europe and Israel      | Predischarge                     | 76             | -                           | 32.9% MoCA         | Worsened score        | Relaxed                  |
|                  | Lansky (2016)           | USA                    | Discharge                        | 36             | -                           | 33.3% MoCA         | Worsened score        | Relaxed                  |
|                  | Van Mieghem (2016)      | Netherlands            | 5 ± 1 days                       | 50             | -                           | 14.0% MMSE         | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  |                |                             | 16.0% MoCA         | Worsened score        | Relaxed                  |
| ≥1 month, <6- months | Zaleska Kockiecka (2018) | Poland                | Discharge                        | 38             | -                           | 42.1% MMSE         | Decrease ≥ 1 point    | Relaxed                  |
|                  | Abawi (2018)            | Netherlands            | 4 months                         | 30             | 81 (6)                      | 30.0% IRMT         | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  |                |                             | 23.3% DRMT         | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  |                |                             | 20.0% RVIT         | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  |                |                             | 30.0% MMSE         | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  |                |                             | 43.3% TMT-A         | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  |                |                             | 63.3% TMT-B         | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  |                |                             | 13.3% CDT           | Worsened score        | Relaxed                  |
|                  | Altisent (2016)         | Spain                  | 79 ± 32 days                     | 34             | -                           | 26.5% GCD          | RCI < −1              | Robust                   |
|                  | Auffret (2016)          | Canada                 | 30 days                          | 40             | -                           | 25.0% Mixed test battery 2 | RCI < −1.645 in ≥ 1 test | Robust                  |
|                  |                         |                        |                                  | 51             | 80 [72–85]                  | 7.8% MoCA          | RCI < −1.645          | Robust                   |
|                  | Fanning (2017)          | Australia              | 6 weeks                          | 31             | 82.4 (7.7)                  | 0% MoCA            | Decrease ≥ 20%        | Robust                   |
|                  | Fanning (2016)          | Australia              | 6 weeks                          | 40             | 81.7 (6.9)                  | 2.5% MoCA          | Decrease ≥ 20%        | Robust                   |
|                  | Haussig (2016)          | Germany                | 30 days                          | 63             | -                           | 42.9% MoCA         | Decrease ≥ 1 point    | Relaxed                  |
|                  | Knipp (2013)            | Germany                | 115.6 ± 49.7 days                | 18             | -                           | 27.8% Mixed test battery 1 | CCS ≤ −2             | Robust                   |
|                  | Lansky (2015)           | Europe and Israel      | 30 days                          | 64             | -                           | 31.3% MoCA         | Worsened score        | Relaxed                  |
|                  | Lansky (2016)           | USA                    | 30 days                          | 32             | -                           | 41.0% MoCA         | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  | 28             | -                           | 32.1% DSST         | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  | 29             | -                           | 20.7% TMT-A (Err)   | Increased errors      | Relaxed                  |
|                  |                         |                        |                                  | 32             | -                           | 37.3% TMT-A (Time)  | Increased time        | Relaxed                  |
|                  |                         |                        |                                  | 19             | -                           | 42.1% TMT-B (Err)   | Increased errors      | Relaxed                  |
|                  |                         |                        |                                  | 30             | -                           | 40.0% TMT-B (Time)  | Increased time        | Relaxed                  |
|                  |                         |                        |                                  | 32             | -                           | 53.1% VF (Letter)   | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  | 32             | -                           | 56.3% VF (Animal)   | Worsened score        | Relaxed                  |
|                  | Orvin (2014)            | Israel                 | 1 month                          | 36             | 82.2 (4.2)                  | 14.3% MMSE         | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  |                |                             | 11.4% Cognistat test | Worsened score        | Relaxed                  |
|                  |                         |                        |                                  |                |                             | 33.3% Rouleau       | Worsened score        | Relaxed                  |

(continued on next page)
Table 1 (Continued)

| Time-point | Study* | Country | Timing of assessment (post-TAVI) | N at time-point | Age at time-point (years)** | Cognitive decline | Cognitive assessment | Cognitive decline definition | Robust/relaxed definition |
|------------|--------|---------|---------------------------------|----------------|-----------------------------|-----------------|----------------|----------------------|--------------------------|
| ≥6-months  | Auffret (2016) | Canada | 1 year                          | 40             | -                           | 30.0%           | Mixed test battery 2 | RCI < -1.645 in ≥ 1 test | Robust                   |
|            | Fanning (2016) | Australia | 6 months                        | 80 [72–85] 40 | 11.8%                       | MoCA            | RCI < -1.645           |                     | Robust                   |
|            | Gleason (2016) | USA     | 1 year                          | 81.7 (6.9) 62 | 0%                          | MoCA            | Decrease ≥ 20%       |                     | Robust                   |
|            | Schoenenberger (2016) | Switzerland | 6-9 months                    | 229            | 8.1%                        | MMSE            | Decrease ≥ 4 points |                     | Robust                   |

* Included study reference list in Supplementary Materials.
** Age in years reported as mean (SD) or median [IQR].

Cognitive composite score ≤ -2 (difference between number of tests with improvement [score difference ≥1SD] and decline [score difference ≤ -1SD]); CDT = Clock-drawing test; DRMT = Delayed recall memory test; DSST = Digit Symbol Substitution Test; GCD = Global cognitive dimension; IRMT = Immediate recall memory test; Mixed test battery 1 = Digit span subtest (Weschler Memory Scale-revised), wordlist subtest (Nümburg age inventory), Regensburg verbal fluency test, MMSE; Mixed test battery 2 = DSST, TMT-A, TMT-B, VF; MMSE = Mini Mental State Examination; MoCA = Montreal Cognitive Assessment; RBANS = Repeatable Battery for the Assessment of Neuropsychological Status; RCI = reliable change index; RVIT = Recognition of verbal information test; TAVI = transcatheter aortic valve implantation; TMT-A = Trail Making Test Part A; TMT-B = Trail Making Test Part B; VF = Verbal Fluency Tests.

Table 2
Summary of included studies which report cognitive improvement following transcatheter aortic valve implantation

| Time-point | Study* | Country | Timing of assessment (post-TAVI) | N at time-point | Age at time-point (years)** | Cognitive decline | Cognitive assessment | Cognitive improvement definition | Robust/relaxed definition |
|------------|--------|---------|---------------------------------|----------------|-----------------------------|-----------------|----------------|----------------------|--------------------------|
| <1-month   | Lansky (2016) | USA     | Discharge                        | 36             | -                           | 50.0%           | MoCA            | Improved score       | Relaxed                   |
| ≥1-month, <6-month | Allisent (2016) | Spain | 79 ± 32 days                    | 34             | -                           | 20.6%           | GCD             | RCI > 1              | Robust                   |
| ≥6-month   | Auffret (2016) | Canada | 30 days                          | 40             | -                           | 40.0%           | Mixed test battery 2 | RCI > 1.645 in ≥ 1 test | Robust                   |
|            | Lansky (2016) | USA     | 30 days                          | 60.7%          | 5.9%                        | MoCA            | RCI > 1.645           |                     | Robust                   |
|            |          |         |                                 | 29             | -                           | 10.3%           | DSST            | Improved score       | Relaxed                   |
|            |          |         |                                 | 29             | -                           | 10.3%           | TMT-A (Err) Decreased errors | Relaxed                   |
|            | Orvin (2014) | Israel  | 1 month                          | 36             | 82.2 (4.2) 32 | 55.6%           | MMSE            | Improved score       | Relaxed                   |
|            | Auffret (2016) | Canada | 1 year                           | 40             | 30.0%                       | Mixed test battery 2 | RCI > 1.645 in ≥ 1 test | Robust                   |
|            | Schoenenberger (2016) | Switzerland | 6-9 months                    | 229            | 7.8%                        | MoCA            | RCI > 1.645           |                     | Robust                   |

* Included study reference list in Supplementary Materials.
** Age in years reported as mean (SD) or median [IQR].

DSST = Digit Symbol Substitution Test; GCD = Global cognitive dimension; Mixed test battery = DSST, TMT-A, TMT-B, VF; MMSE = Mini Mental State Examination; MoCA = Montreal Cognitive Assessment; RCI = reliable change index; TAVI = transcatheter aortic valve implantation; TMT-A = Trail Making Test Part A; TMT-B = Trail Making Test Part B; VF = Verbal Fluency Tests.
available to split the risk factor analysis for cerebral protection device into 2 time-points; up to 1-week/discharge, and 1-month post-TAVI; all other data were merged across time-points.

Using a cerebral protection device was significantly associated with lower prevalence of cognitive decline up to 1-week post-TAVI (OR 0.47, 95% CI 0.25 to 0.90, p = 0.022). However, at 1-month post-TAVI, using a cerebral protection device was not significantly associated with prevalence of cognitive decline (OR 1.00, 95% CI 0.48 to 2.07, p = 0.993). No other factors were significantly associated with cognitive decline.

Protective factors for cognition after TAVI were not commonly reported. The only factor that was reported by more than 1 paper was baseline cognitive impairment. As such, baseline cognitive impairment was the sole variable meta-analyzed for the development of cognitive improvement (see Table 3 and Supplement Table 5), with the association found to be significant (OR 14.5, 95% CI 5.8 to 36.5, p < 0.001).

Discussion

This meta-analysis synthesized available data representing cognitive decline and improvement in TAVI patients over time. Studies using relaxed definitions of cognitive change (which do not account for measurement error and practice effects) likely overestimated the incidence and clinical significance of both cognitive decline and improvement. To account for normal individual variation in cognitive tests over time, we suggest current best estimates for prevalence of cognitive decline and improvement after TAVI come from robust cognitive change definitions. As such, we report that best estimates of prevalence of cognitive decline up to 1-month, 1 to 6-months, and ≥6-months post-TAVI are 7%, 14%, and 12%, respectively (robust estimates). For cognitive improvement, the prevalence from 1 to 6 months, and ≥6 months after TAVI is estimated at 19% and 11%, respectively (robust estimates).

Caution should be employed when interpreting these results as pooled estimates are not directly comparable across time-points and between cognitive decline and improvement because they represent different individuals. Results do seem to indicate that cognitive decline and improvement are both commonly occurring outcomes after TAVI procedures, with incidence of cognitive decline and improvement estimated to be between 7% and 19% in the 6 months after TAVI.

It appears as though equivalent numbers (given CIs overlap) of TAVI patients experience cognitive decline and cognitive improvement, which has given rise to the null findings using a whole-group-analysis approach previously. However, it is critical that we try to understand the heterogeneity in this effect, including those at high risk of cognitive decline and improvement post-TAVI. If we can understand the predictive factors for cognitive decline and improvement, we can provide personalized care and improve prognosis.

We found minimal consistent reporting of risk factors for cognitive decline after TAVI in the literature. As such, we were only able to meta-analyze the effects of 10 factors on their contribution to cognitive decline. Of the analyzed factors, only use of a cerebral protection device was found to have a statistically significant association with lower prevalence of cognitive decline up to 1-week post-TAVI, which was no longer significant at 1 month. As patients in these studies either used a protection device or did not, patient characteristics may have influenced these associations.

Cognitive improvement is a relatively common outcome after TAVI, occurring in an estimated 19% of patients up to 6-months postprocedure. Baseline cognitive impairment was the only factor able to be analyzed and was found to have a large association with post-TAVI cognitive improvement. Those with the lowest cognitive function pre-TAVI have the most to gain post-TAVI; but it also may be the case that ceiling effects existed within some of the tests used in contributing studies (partly driving this effect). With a large proportion of the generally older population who underwent TAVI presenting with preprocedure cognitive impairment (approx. 30%), these results suggest there is great potential for cognitive improvement after TAVI in these patients.

Limited reporting of risk factors meant the effect of important variables on cognitive outcomes after TAVI were
### Table 3
Meta-analyses on pre-, intra-, and postprocedural variables for the development of cognitive decline and cognitive improvement following transcatheter aortic valve implantation

| Variable                              | Studies                                           | Time-point of decline | N   | OR or MD* (95% CI) | p value | Heterogeneity |
|----------------------------------------|---------------------------------------------------|----------------------|-----|-------------------|---------|---------------|
| **Factors associated with cognitive decline** |                                                   |                      |     |                   |         |               |
| Preprocedural                          |                                                   |                      |     |                   |         |               |
| Age                                    | Ghanem, 2013; Schoenenberger 2016                 | All                  | 340 | 1.44* (-2.05−4.92) | 0.420   | \(I^2 = 48.36, \text{df} = 1, p = 0.164\) |
| AF                                     | Ghanem, 2013; Lansky, 2015; Schoenenberger, 2016 | All                  | 410 | 1.57 (0.84−2.92)   | 0.156   | \(I^2 = 0, \text{df} = 2, p = 0.374\) |
| BMI                                    | Ghanem, 2013; Schoenenberger, 2016                | All                  | 340 | 0.73* (-1.21−2.66) | 0.462   | \(I^2 = 0, \text{df} = 1, p = 0.655\) |
| Diabetes                               | Ghanem, 2013; Schoenenberger, 2016                | All                  | 340 | 0.76 (0.32−1.82)   | 0.535   | \(I^2 = 0, \text{df} = 1, p = 0.560\) |
| Gender                                 | Ghanem, 2013; Schoenenberger, 2016                | All                  | 340 | 1.27 (0.62−2.59)   | 0.507   | \(I^2 = 26.88, \text{df} = 1, p = 0.242\) |
| Hypertension                           | Ghanem, 2013; Schoenenberger, 2016                | All                  | 340 | 1.33 (0.16−10.84)  | 0.787   | \(I^2 = 0, \text{df} = 1, p = 0.560\) |
| Baseline CI                            | Ghanem, 2013; Schoenenberger, 2016                | All                  | 340 | 0.79 (0.26−2.36)   | 0.668   | \(I^2 = 0, \text{df} = 1, p = 0.328\) |
| Stroke/TIA                             | Ghanem, 2013; Schoenenberger, 2016                | All                  | 340 | 1.35 (0.48−3.81)   | 0.568   | \(I^2 = 0, \text{df} = 1, p = 0.294\) |
| **Intraprocedural**                    |                                                   |                      |     |                   |         |               |
| Cerebral protection device             | Haussig, 2016; Lansky, 2015; VanMieghem, 2016     | Up to 1-week/discharge | 198 | 0.47 (0.25−0.90)   | 0.022   | \(I^2 = 0, \text{df} = 2, p = 0.608\) |
| Postprocedural                         |                                                   |                      |     |                   |         |               |
| Stroke                                 | Ghanem, 2013*; Gleason, 2016; Lansky, 2016; Schoenenberger, 2016 | All                  | 325 | 0.54 (0.11−2.71)   | 0.452   | \(I^2 = 22.02, \text{df} = 2, p = 0.277\) |
| **Factors associated with cognitive improvement** |                                                   |                      |     |                   |         |               |
| Baseline CI                            | Auffret, 2016; Schoenenberger, 2016               | All                  | 280 | 14.54 (5.79−36.52) | <0.001  | \(I^2 = 0, \text{df} = 1, p = 0.357\) |

* No patients had a post-procedure stroke.

1Any stroke or TIA.
2Stroke based on VARC-2 criteria.
3Stroke/MI within 30 days, based on VARC criteria.

AF = atrial fibrillation; BMI = body mass index; CI = cognitive impairment; MD = mean difference; OR = odds ratio; TIA = transient ischemic attack.
unable to be analyzed. This general lack of information on predictors of cognitive decline post-TAVI is somewhat surprising considering a recent meta-analysis which identified 8 risk factors for delirium after TAVI. Delirium is another incident cognitive impairment, but one which is temporary. As such, the impact of risk factors identified for delirium, including acute kidney injury, transapical approach, and carotid artery disease, on post-TAVI cognitive decline should be measured in future studies. An investigation of risk factors previously identified for cognitive decline after heart surgery, particularly depression, in relation to post-TAVI cognitive outcomes would also be useful. Such information will allow a more comprehensive analysis of the predictors of cognitive decline and improvement after TAVI.

It should be noted that 3 of the reported risk factors for delirium after TAVI (hypertension, atrial fibrillation, previous stroke) were also assessed in the current study and were not associated with post-TAVI cognitive decline. Additionally, whereas Tilley et al. showed pre-TAVI cognitive impairment as a risk factor for delirium, in the current study baseline cognitive impairment was associated with cognitive improvement. To better inform clinical practice, further research is needed to compare predictive factors for cognitive decline and delirium after TAVI. These contrary findings may be due to smaller sample sizes here, and the assessment of subgroups rather than whole-group averages.

Although this meta-analysis was the first to synthesize available literature and report the prevalence of cognitive decline and improvement after TAVI, it was not without limitations. Only 15 studies met inclusion criteria, resulting in smaller sample sizes within analyses. Moderate to large heterogeneity was found in prevalence analyses at all time-points which included both relaxed and robust definitions of cognitive change. Splitting analyses by these definitions increased homogeneity. The reliable change index method, which corrects for practice and ageing effects, has been shown to perform well in signifying change associated with a change in diagnostic status. We suggest future studies should employ a reliable change index method for classifying significant cognitive change, as it considers individual change in comparison to the group but does not utilize arbitrary cutoffs. Furthermore, the scarcity of risk factors reported in included studies made a comprehensive analysis of predictors of cognitive change after TAVI unable to be completed. More research is required in this area which reports potential predictors of cognitive change post-TAVI (e.g., depression, acute kidney injury, and transapical approach).

TAVI has quickly gained traction as the standard-of-care in the treatment of severe, symptomatic aortic stenosis for individuals ineligible for the surgical alternative. Notably, the current review highlighted that cognitive decline, an important but often overlooked post-TAVI outcome, is just as frequent an occurrence as cognitive improvement (ranging from 7% to 19%). The current paper also revealed that most individuals, approximately 81% to 93%, do not experience any long-term cognitive change post-TAVI. Assessment of these subgroups will enable a personalized medicine approach in TAVI, particularly the development and targeting of neuroprotective strategies in those at high risk of cognitive decline.

Declaration of Interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Disclosures

The authors report no relationships that could be construed as a conflict of interest.

Acknowledgment

The authors gratefully acknowledge the input of Erica Tilley, McInlSci.

Supplementary materials

Supplementary material associated with this article can be found in the online version at https://doi.org/10.1016/j.amjcard.2020.04.023.
statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W-65–W-94.

12. Joanna Briggs Institute. Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence Data. Adelaide: Joanna Briggs Institute; 2011.

13. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3, 2013, Englewood, NJ: Biostat.

14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560.

15. Altisent OA-J, Ferreira-Gonzalez I, Marsal JR, Ribera A, Auger C, Ortega G, Cascant P, Urena M, Del Blanco BG, Serra V, Sureda C, Igual A, Rovira A, Gonzalez-Alujas MT, Gonzalez A, Puri R, Cuellar H, Tornos P, Rodes-Cabau J, Garcia-Dorado D. Neurological damage after transcatheter aortic valve implantation compared with surgical aortic valve replacement in intermediate risk patients. Clin Res Cardiol 2016;105:508–517.

16. Auffret V, Campelo-Parada F, Regueiro A, Del Trigo M, Chiche O, Chamandi C, Allende R, Cordoba-Soriano JG, Paradis JM, De Larochellière R, Doyle D, Dumont E, Mohammadi S, Cote M, Marrero A, Puri R, Rodes-Cabau J. Serial changes in cognitive function following transcatheter aortic valve replacement. J Am Coll Cardiol 2016;68:2129–2141.

17. Fanning JP, Walters DL, Wesley AJ, Anstey C, Huth S, Bellapart J, Collard C, Raschuk IL, Natani S, Savage M, Fraser JF. Intraoperative cerebral perfusion disturbances during transcatheter aortic valve replacement. Ann Thorac Surg 2017;104:1564–1568.

18. Fanning JP, Wesley AJ, Walters DL, Eeles EM, Barnett AG, Platts DG, Clarke AJ, Wong AA, Strugnell WE, O’Sullivan C, Tronstad O, Fraser JF. Neurological injury in intermediate–risk transcatheter aortic valve implantation. J Am Coll Cardiol 2017;69:1596–1605.

19. Gleason TG, Schindler JT, Adams DH, Reardon MJ, Kleiman NS, Caplan LR, Conte JV, Deeb GM, Hughes GC Jr, Chenoweth S, Popma JJ. The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement. J Thorac Cardiovasc Surg 2016;152:85–96.

20. Schoenengerber AW, Zuber C, Moser A, Zwahlen M, Wenaweser P, Windecker S, Carrel T, Stuck AE, Stortecky S. Evolution of cognitive function after transcatheter aortic valve implantation. Circ Cardiovasc Interv 2016;9:e003590.

21. Lansky AJ, Brown D, Pena C, Pietras CG, Parise H, Ng VG, Meller S, Abrams KJ, Cleman M, Margolis P, Petrossian G, Brickman AM, Voros S, Moses J, Forrest JK. Neurologic complications of unprotected transcatheter aortic valve implantation (from the Neuro-TAVI Trial). Am J Cardiol 2016;118:1519–1526.

22. Alkhali A, Golbani S, Song D, Lamba H, Fares A, Alaiti A, Deo S, Attizzani GF, Ibrahim H, Ruiz CE. In–hospital outcomes of transcatheter versus surgical aortic valve replacement in end stage renal disease. Catheter Cardiovasc Interv 2018;92:757–765.

23. Schoenengerber AW, Stortecky S, Neumann S, Moser A, Jüni P, Carrel T, Huber C, Gandon M, Bischoff S, Schoenengerber C-M, Stuck AE, Windecker S, Wenaweser P. Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J 2013;34:684–692.

24. Stortecky S, Schoenengerber AW, Moser A, Kalesan B, Jüni P, Carrel T, Bischoff S, Schoenengerber C-M, Stuck AE, Windecker S, Wenaweser P. Evaluation of multidimensional geriatric assessment as a predictor of mortality and cardiovascular events after transcatheter aortic valve implantation. JACC Cardiovasc Interv 2012;5:489–496.

25. Tse L, Bowering JB, Schwarz SK, Moore RL, Burns KD, Barr AM. Postoperative delirium following transcatheter aortic valve implantation: a historical cohort study. Can J Anesth Can Anesthesie 2015;62:22–30.

26. Tilley E, Psaltis PJ, Loetscher T, Davis DH, Harrison SL, Kim S, Keage HAD. Meta-analysis of prevalence and risk factors for delirium after transcatheter aortic valve implantation. Am J Cardiol 2018;122:1917–1923.

27. Fong TG, Davis D, Growdon ME, Albuquerque A, Inouye SK. The interface between delirium and dementia in elderly adults: Lancet Neurol 2015;14:823–832.

28. Greaves D, Psaltis PJ, Davis D, Ross T, Ghezzi E, Lampit A, Smith A, Keage HAD. Risk factors for delirium and cognitive decline following coronary artery bypass grafting surgery: a systematic review and meta-analysis. Under review.

29. Frerichs RJ, Tuokko HA. A comparison of methods for measuring cognitive change in older adults. Arch Clin Neuropsychol 2005;20:321–333.